← Leaderboards
John Nathaniel Diehl
Univ Of North Carolina Chapel Hill
$180,426
Attributed
$180,426
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $51K · FY2019–22$100K$75K$50K$25K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$180,426 · 1
By mechanism
F30$180,426 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Jen Jen Yeh$14,819,320
- Yuliya Pylayeva-Gupta$4,145,109
- Irving C Allen$4,589,595
- Nigel Mackman$23,794,157
- Lee M Graves$9,136,757
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteApoptosisBaseBioinformatics ToolCancer BiologyCancer CellCancer EtiologyCaringCategoriesCell CycleCell Cycle RegulationCell LineCell ModelCellsCellular BiologyChemotherapyClinical CandidateClinical DevelopmentCollaborationsColorectal CancerComprehensive Cancer CenterComputational BiologyComputerized ToolsCytotoxic Agent
Grant awards (4)
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer$48,989
F30 · FY2022 · CA · contact PI
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer$51,036
F30 · FY2021 · CA · contact PI
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer$43,878
F30 · FY2020 · CA · contact PI
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer$36,523
F30 · FY2019 · CA · contact PI